A detailed history of Virtus ETF Advisers LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 5,047 shares of CRSP stock, worth $241,650. This represents 0.12% of its overall portfolio holdings.

Number of Shares
5,047
Previous 5,047 -0.0%
Holding current value
$241,650
Previous $272,000 12.87%
% of portfolio
0.12%
Previous 0.14%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$51.17 - $68.18 $51,528 - $68,657
-1,007 Reduced 16.63%
5,047 $272,000
Q1 2024

May 15, 2024

BUY
$60.67 - $89.12 $52,843 - $77,623
871 Added 16.8%
6,054 $412,000
Q4 2023

Feb 15, 2024

BUY
$38.62 - $72.18 $135,247 - $252,774
3,502 Added 208.33%
5,183 $324,000
Q3 2023

Nov 07, 2023

SELL
$45.39 - $59.0 $7,398 - $9,617
-163 Reduced 8.84%
1,681 $76,000
Q2 2023

Aug 14, 2023

SELL
$43.47 - $67.77 $7,520 - $11,724
-173 Reduced 8.58%
1,844 $103,000
Q1 2023

May 15, 2023

SELL
$41.0 - $56.12 $31,734 - $43,436
-774 Reduced 27.73%
2,017 $91,000
Q4 2022

Feb 14, 2023

BUY
$39.19 - $65.67 $39,033 - $65,407
996 Added 55.49%
2,791 $113,000
Q3 2022

Nov 14, 2022

BUY
$61.1 - $83.78 $672 - $921
11 Added 0.62%
1,795 $117,000
Q2 2022

Aug 12, 2022

SELL
$43.23 - $73.83 $12,839 - $21,927
-297 Reduced 14.27%
1,784 $108,000
Q1 2022

May 16, 2022

SELL
$53.19 - $79.24 $6,489 - $9,667
-122 Reduced 5.54%
2,081 $131,000
Q4 2021

Feb 14, 2022

BUY
$70.09 - $111.29 $39,180 - $62,211
559 Added 34.0%
2,203 $167,000
Q3 2021

Nov 15, 2021

SELL
$110.2 - $156.64 $10,248 - $14,567
-93 Reduced 5.35%
1,644 $184,000
Q2 2021

Aug 10, 2021

SELL
$100.84 - $161.89 $26,823 - $43,062
-266 Reduced 13.28%
1,737 $281,000
Q1 2021

May 17, 2021

BUY
$110.72 - $210.04 $4,096 - $7,771
37 Added 1.88%
2,003 $244,000
Q4 2020

Feb 12, 2021

SELL
$79.67 - $173.23 $254,067 - $552,430
-3,189 Reduced 61.86%
1,966 $301,000
Q3 2020

Nov 13, 2020

SELL
$78.5 - $100.64 $54,086 - $69,340
-689 Reduced 11.79%
5,155 $431,000
Q2 2020

Aug 05, 2020

BUY
$38.5 - $76.05 $13,359 - $26,389
347 Added 6.31%
5,844 $429,000
Q1 2020

May 14, 2020

SELL
$33.68 - $62.53 $27,247 - $50,586
-809 Reduced 12.83%
5,497 $233,000
Q4 2019

Feb 13, 2020

BUY
$36.68 - $73.13 $231,304 - $461,157
6,306 New
6,306 $384,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.74B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.